A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

StatusActive, Not Recruiting

PhaseNot specified

SponsorHoffmann-La Roche

Started2023-08-25

View on ClinicalTrials.gov ↗

Amendment history

2026-10-01

Enrollment closed, study ongoing

2026-06-30

Study Status, Contacts/Locations v31

Trial status changed: Active, Not Recruiting → Recruiting

Study sitesdetails revised at 29 of 29 sites

2026-04-30

4 amendments v27-v30

4 re-verifications since 2025-08-05, no change to tracked fields

2025-07-04

Study Status, Contacts/Locations v26

Study sitesdetails revised at 1 of 29 sites

2025-06-03

Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v25

Trial statusRecruiting→Active, Not Recruiting

Study sitesdetails revised at 29 of 29 sites

Show 24 earlier versions

2025-05-02

Study Status v24

Re-verified, no change to tracked fields

2025-04-04

Study Status, Contacts/Locations v23

Study sites28→29

2025-03-07

Study Status, Contacts/Locations v22

Study sites27→28

2025-02-06

Study Status v21

Primary completion date2026-12-31→2027-05-31

Completion date2026-12-31→2027-05-31

2025-01-03

Study Status, Contacts/Locations v20

Study sites31→27

2024-12-06

Study Status, Contacts/Locations, IPDSharing v19

Study sites28→31

2024-11-06

Study Status v18

Re-verified, no change to tracked fields

2024-10-08

Study Status v17

Primary completion date2026-09-30→2026-12-31

Completion date2026-09-30→2026-12-31

2024-10-04

2 amendments v15-v16

2 re-verifications since 2024-08-29, no change to tracked fields

2024-07-30

Study Status, Contacts/Locations v14

Study sites26→28

2024-07-01

Study Status, Contacts/Locations v13

Study sitesdetails revised at 1 of 26 sites

2024-06-05

Study Status v12

Re-verified, no change to tracked fields

2024-05-10

Study Status, Contacts/Locations v11

Study sites25→26

2024-04-16

Study Status, Contacts/Locations v10

Study sites23→25

2024-03-22

Study Status, Contacts/Locations v9

Study sites22→23

2024-02-26

Study Status, Contacts/Locations v8

Study sitesdetails revised at 1 of 22 sites

2024-01-29

Study Status, Contacts/Locations v7

Study sites17→22

2024-01-01

Study Status, Contacts/Locations v6

Study sites13→17

2023-12-04

Study Status, Contacts/Locations v5

Study sites8→13

2023-11-06

Study Status, Contacts/Locations v4

Study sites3→8

2023-10-09

Study Status, Contacts/Locations v3

Study sites2→3

2023-09-11

Study Status, Contacts/Locations v2

Start dateestimated 2023-09-10→confirmed 2023-08-25

Study sites1→2

2023-08-25

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start date2023-07-30→2023-09-10

Study sites0→1

2023-07-12

Original filing

Roche/Genentech

364 trials monitored

See 34 trials at risk

Non-Hodgkin Lymphoma

1,512 trials monitored

See 79 trials at risk

DLBCL

648 trials monitored

See 32 trials at risk

The purpose of this study is to assess the progression free survival (PFS) in the real-world settings of polatuzumab among Chinese diffuse large B cell lymphoma (DLBCL) participants.

Trial Details

NCT Number	NCT05954910
Lead Sponsor	Hoffmann-La Roche
Conditions	Diffuse Large B-Cell Lymphoma
Enrollment	1,000 participants
Start Date	2023-08-25
Primary Completion	2027-05-31 (estimated)
Study Completion	2027-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-30